Provention Bio (PRVB) Stock Price
Provention Bio Price
Provention Bio's net margin stands at -880.7%, up from -8,203.0% several years earlier.
Provention Bio stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Provention Bio business model & stock analysis
Frequently asked questions about Provention Bio
Provention Bio Inc is primarily active in the biotechnology industry.
The main competitors of Provention Bio Inc in the market are companies such as Eli Lilly and Company, Novo Nordisk A/S, and Sanofi SA.
The business model of Provention Bio Inc. focuses on the development and commercialization of therapeutics and solutions for the prevention and interception of immune-mediated diseases. Provention Bio Inc. primarily targets chronic autoimmune and inflammatory diseases, such as type 1 diabetes, Crohn's disease, and lupus. The company utilizes innovative approaches, including advanced diagnostics, predictive analytics, and precision medicine, to identify individuals at high risk of developing these diseases and intervene early with preventive treatments. Provention Bio Inc. aims to improve patient outcomes and quality of life by effectively managing immune-mediated diseases through their comprehensive approach.
Provention Bio Inc is a biopharmaceutical company specializing in the development of immune-based therapies. Founded in 2016, Provention Bio Inc has emerged as a leader in innovative treatments for autoimmune diseases. The company's focus lies in identifying and advancing therapeutic candidates that target the underlying causes of these diseases. With a strong commitment to research and development, Provention Bio Inc has established strategic partnerships and collaborations to accelerate its pipeline and bring novel therapies to patients. This dedication has positioned Provention Bio Inc as a key player in the field, poised to address unmet medical needs and make a lasting impact.
Provention Bio Inc. has achieved several significant milestones since its establishment. Notably, the company successfully completed a Phase 2B trial for its lead product candidate, PRV-031, in patients with type 1 diabetes. Provention Bio Inc. also received Breakthrough Therapy designation from the U.S. FDA for PRV-031, highlighting its potential to address the unmet medical needs in type 1 diabetes. Additionally, the company entered into a licensing agreement with Janssen Biotech Inc. to develop and commercialize PRV-6527, a potential treatment for Crohn's disease. These achievements demonstrate Provention Bio Inc.'s dedication to developing innovative therapies that offer hope to patients suffering from debilitating diseases.
Provention Bio Inc primarily operates in the United States.
Provention Bio Inc represents a commitment to innovation, integrity, and patient-centricity. As a leading biopharmaceutical company, Provention Bio is focused on developing transformative therapies to intercept and prevent immune-mediated diseases. The company aims to address unmet medical needs, prioritize patient well-being, and improve healthcare outcomes worldwide. With a visionary corporate philosophy, Provention Bio is dedicated to advancing novel treatments through rigorous research, strategic collaborations, and a deep understanding of autoimmune disorders. By prioritizing scientific excellence and patient advocacy, Provention Bio is poised to make a significant impact in the field of immune-mediated diseases.
12 analysts currently rate the Provention Bio stock: 8 recommend buying, 4 holding and 0 selling.
The Provention Bio share (PRVB) is listed on 5 stock exchanges, including: NASDAQ (PRVB), Frankfurt (2VB.F), München (2VB.MU), Düsseldorf (2VB.DU), Hamburg (2VB.HM).
Provention Bio Inc is a biopharmaceutical company specializing in the prevention of autoimmune diseases and other chronic illnesses. The company operates in several areas, including clinical research, product development, and partnerships. The clinical research focuses on identifying new therapies and diagnoses for autoimmune diseases such as type 1 diabetes, celiac disease, and lupus. The product development includes the development of preventive therapies for type 1 diabetes and diagnostic tools for autoimmune diseases. Partnerships with universities, bio-pharmaceutical companies, and other academic institutions are also an important part of the company's business model.
The revenue cannot currently be calculated for Provention Bio.
The profit cannot currently be calculated for Provention Bio.
The P/E ratio cannot be calculated for Provention Bio at the moment.
The P/S cannot be calculated for Provention Bio currently.
The Eulerpool Quality Score for Provention Bio is 3/10.
The ISIN of Provention Bio is US74374N1028. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Provention Bio is A2JRLW. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Provention Bio is PRVB. The ticker symbol is used to trade Provention Bio shares on the stock exchange.
Provention Bio stock
Provention Bio Peer Group
Provention Bio Ticker
All fundamentals and in-depth analysis of Provention Bio
Our stock analysis for Provention Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Provention Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.